Publication | Closed Access

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Cnto 888MedicineHuman Monoclonal AntibodyImmunologyImmune Checkpoint InhibitorTumor TargetingAnti-cancer AgentCancer TreatmentPhase 2OncologyRadiation Oncology